Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 5911 AL 5925

Impaired attention in the 3xTgAD mouse model of Alzheimer's disease: rescue by donepezil (Aricept)

Romberg C, Mattson MP, Mughal MR, Bussey TJ, Saksida LM.

J Neurosci. 2011 Mar 2;31(9):3500-7. doi: 10.1523/JNEUROSCI.5242-10.2011.

When will Alzheimer's disease be cured? A pharmaceutical perspective

Townsend M.

J Alzheimers Dis. 2011;24 Suppl 2:43-52. doi: 10.3233/JAD-2011-110020.

Animal models in the drug discovery pipeline for Alzheimer's disease

Van Dam D, De Deyn PP.

Br J Pharmacol. 2011 Oct;164(4):1285-300. doi: 10.1111/j.1476-5381.2011.01299.x.

Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials

Menéndez-González M, Pérez-Piñera P, Martínez-Rivera M, Muñiz AL, Vega JA.

Curr Pharm Des. 2011;17(5):508-20. doi: 10.2174/138161211795164112.

Memantine in dementia: a review of the current evidence

Herrmann N, Li A, Lanctôt K.

Expert Opin Pharmacother. 2011 Apr;12(5):787-800. doi: 10.1517/14656566.2011.558006. Epub 2011 Mar 9.

Effects of anticholinergic drugs on cognitive function in older Australians: results from the AIBL study

Sittironnarit G, Ames D, Bush AI, Faux N, Flicker L, Foster J, Hilmer S, Lautenschlager NT, Maruff P, Masters CL, Martins RN, Rowe C, Szoeke C, Ellis KA; AIBL research group.

Dement Geriatr Cogn Disord. 2011;31(3):173-8. doi: 10.1159/000325171. Epub 2011 Mar 9.

Drug delivery strategies for Alzheimer's disease treatment

Di Stefano A, Iannitelli A, Laserra S, Sozio P.

Expert Opin Drug Deliv. 2011 May;8(5):581-603. doi: 10.1517/17425247.2011.561311. Epub 2011 Mar 11.

Activation of the α-secretase processing of AβPP as a therapeutic approach in Alzheimer's disease

Vincent B, Govitrapong P.

J Alzheimers Dis. 2011;24 Suppl 2:75-94. doi: 10.3233/JAD-2011-110218.

Amyloid clearance as a treatment target against Alzheimer's disease

Kurz A, Perneczky R.

J Alzheimers Dis. 2011;24 Suppl 2:61-73. doi: 10.3233/JAD-2011-102139.

Targeting the kynurenine pathway-related alterations in Alzheimer's disease: a future therapeutic strategy

Plangár I, Zádori D, Klivényi P, Toldi J, Vécsei L.

J Alzheimers Dis. 2011;24 Suppl 2:199-209. doi: 10.3233/JAD-2011-110131.

Corticosteroids, but not NSAIDs, are associated with less Alzheimer neuropathology

Beeri MS, Schmeidler J, Lesser GT, Maroukian M, West R, Leung S, Wysocki M, Perl DP, Purohit DP, Haroutunian V.

Neurobiol Aging. 2012 Jul;33(7):1258-64. doi: 10.1016/j.neurobiolaging.2011.02.011. Epub 2011 Apr 1.

Membrane anchored and lipid raft targeted β-secretase inhibitors for Alzheimer's disease therapy

Ben Halima S, Rajendran L.

J Alzheimers Dis. 2011;24 Suppl 2:143-52. doi: 10.3233/JAD-2011-110269.

Memantine in moderate to severe Alzheimer's disease: an observational post-marketing study

Rainer M, Wuschitz A, Jagsch C, Erb C, Chirikdjian JJ, Mucke HA.

J Neural Transm (Vienna). 2011 Aug;118(8):1255-9. doi: 10.1007/s00702-011-0623-8. Epub 2011 Apr 2.

Public financial support receipt and non-medical resource utilization in Alzheimer's disease results from the PLASA study

Rapp T, Grand A, Cantet C, Andrieu S, Coley N, Portet F, Vellas B.

Soc Sci Med. 2011 Apr;72(8):1310-6. doi: 10.1016/j.socscimed.2011.02.039. Epub 2011 Mar 21.

Rehabilitating a brain with Alzheimer's: a proposal

Aranda-Abreu GE, Hernández-Aguilar ME, Manzo Denes J, García Hernández LI, Herrera Rivero M.

Clin Interv Aging. 2011;6:53-9. doi: 10.2147/CIA.S14008. Epub 2011 Feb 22.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias